市場調査レポート

商品コード

1193310

制吐剤市場：薬剤タイプ別、用途別、流通チャネル別：世界の機会分析・産業予測、2021-2031年

Antiemetics Market By Drug Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年11月01日 | 発行: Allied Market Research

| ページ情報: 英文 260 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の制吐剤市場は、2021年に22億5168万米ドル、2031年には40億6136万米ドルに達すると予測され、2022年から2031年までのCAGRは6.1%を記録しています。

嘔吐は、吐出とも呼ばれ、口や鼻から不随意に、強制的に胃の外に物質を排出することを指し、この不随意の排出を止めるために使われる薬が制吐剤と呼ばれる。船酔いなどの乗り物酔い、妊娠初期、強い痛み、化学毒素への暴露、感情的ストレス（恐怖）、胆嚢疾患、食中毒、消化不良などは、嘔吐を伴う一般的な原因の一部です。また、化学療法、胃腸炎、全身麻酔、腸閉塞、片頭痛などの重篤な疾患も、患者の吐き気や嘔吐につながる可能性があります。

化学療法の増加は、制吐剤市場の成長を促す主要な要因の1つです。米国がん協会（ACS）によると、米国では2022年に609,360人のがん死亡者と190万人の新規患者が発生すると予想されています。男女合わせてのがん死亡率は、1991年の最高値から2019年には32%に減少しています。この死亡率の低下には、化学療法や放射線療法など、患者によるさまざまながん治療の採用が急増していることが主な原因となっています。化学療法や放射線療法の使用は、これらの治療が吐き気や嘔吐などの副作用を伴うため、制吐剤の需要を高めると予想されます。このように、がん患者の高い有病率と治療オプションとしての化学療法の広範な使用は、予測期間中に世界の制吐剤市場に燃料を供給すると予想されます。

さらに、各国政府や民間団体による製造装置への資金提供の増加も、市場の成長を後押しすると予想されます。また、各国の政府機関は、新しい分子の研究開発を行うための資金を提供しており、その地域の市場の成長を後押ししています。さらに、主要な市場参加者による買収や提携も、市場の押し上げ要因となっています。これらの主要戦略は、主に主要な市場プレーヤーが自社のビジネスとその製品ポートフォリオを拡大するために採用され、市場の成長とともに、企業の売上高の増加につながります。

さらに、胃腸炎の発生は、市場の成長に寄与しています。胃腸炎は、通常、ウイルス、細菌、寄生虫に感染した食物や水によって引き起こされる胃や腸の炎症です。胃の不快感やけいれんに加え、吐き気、発熱、けいれん、頭痛などを生じます。さらに、ノロウイルスは、米国で胃腸炎や食中毒の発生源として著名であり、患者に吐き気や嘔吐を引き起こします。このようなノロウイルス感染症の流行は、制吐剤に対する需要を高め、同地域における制吐剤の売上を増加させ、市場全体の成長を押し上げています。

しかし、制吐剤に対する認知度が低いことが市場の成長を妨げています。また、処方された制吐剤の強さや用量、薬効分類が患者の病状を悪化させる場合があり、薬とその薬理学に関する正しい知識が必要とされ、これが制吐剤市場の抑制要因となる可能性があります。その一方で、主な市場参加者による研究開発活動の活発化と医療費の増加は、多くの主な参加者の新興国市場への参入をさらに促し、制吐剤市場の拡大のための有利な機会を提供しています。また、アジアやLAMEAなどの新興国市場には原料が豊富に存在するため、市場関係者に投資する有利な機会を提供しています。

概要
- 市場規模および予測
抗ヒスタミン薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
セロトニン受容体拮抗薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ドパミン受容体拮抗薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ニューロキニン受容体拮抗薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
抗コリン剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他の薬剤タイプ
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章制吐剤市場：用途別

概要
- 市場規模および予測
化学療法
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
術後外科手術
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
妊娠・胃腸炎
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他の用途
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章制吐剤市場：流通チャネル別

概要
- 市場規模・予測
小売薬局
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場分析：国別
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
オンライン薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章制吐剤市場：地域別

概要
- 市場規模・予測
北米
- 主な動向と機会
- 北米市場規模・予測：薬剤タイプ別
- 北米市場規模・予測：用途別
- 北米市場規模・予測：流通チャネル別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主要動向と機会
- 欧州の市場規模・予測：薬剤タイプ別
- 欧州市場規模・予測：用途別
- 欧州市場規模・予測：流通チャネル別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：薬剤タイプ別
- アジア太平洋地域の市場規模・予測：用途別
- アジア太平洋地域の市場規模・予測：流通チャネル別
- アジア太平洋地域の市場規模・予測：国別
  - 中国
  - 日本
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：薬剤タイプ別
- LAMEAの市場規模・予測：用途別
- LAMEAの市場規模・予測：流通チャネル別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

GlaxoSmithKline Plc
Sanofi
Novartis AG
Pfizer Inc
Merck & Co. Inc
Dr. Reddy's Laboratories Ltd
Cipla
Johnson & Johnson
Torrent Pharmaceuticals Ltd
Acacia Pharma Group

図表

LIST OF TABLES

TABLE 1. GLOBAL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 2. ANTIEMETICS MARKET, FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
TABLE 3. ANTIEMETICS MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. ANTIEMETICS MARKET, FOR SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. ANTIEMETICS MARKET FOR SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. ANTIEMETICS MARKET, FOR DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. ANTIEMETICS MARKET FOR DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. ANTIEMETICS MARKET, FOR NEUROKININ RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. ANTIEMETICS MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. ANTIEMETICS MARKET, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. ANTIEMETICS MARKET FOR ANTICHOLINERGICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. ANTIEMETICS MARKET, FOR OTHER DRUG TYPES, BY REGION, 2021-2031 ($MILLION)
TABLE 13. ANTIEMETICS MARKET FOR OTHER DRUG TYPES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 15. ANTIEMETICS MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 16. ANTIEMETICS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. ANTIEMETICS MARKET, FOR POST OPERATIVE SURGERY, BY REGION, 2021-2031 ($MILLION)
TABLE 18. ANTIEMETICS MARKET FOR POST OPERATIVE SURGERY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. ANTIEMETICS MARKET, FOR PREGNANCY AND GATROENTERITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. ANTIEMETICS MARKET FOR PREGNANCY AND GATROENTERITIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. ANTIEMETICS MARKET, FOR OTHER APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. ANTIEMETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. GLOBAL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. ANTIEMETICS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 25. ANTIEMETICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. ANTIEMETICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 27. ANTIEMETICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. ANTIEMETICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 29. ANTIEMETICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. ANTIEMETICS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 36. U.S. ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 37. U.S. ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 39. CANADA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 40. CANADA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 42. MEXICO ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 43. MEXICO ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. EUROPE ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 48. GERMANY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 49. GERMANY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 50. GERMANY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 51. FRANCE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 52. FRANCE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 53. FRANCE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 54. UK ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 55. UK ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 56. UK ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 57. ITALY ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 58. ITALY ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. ITALY ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 60. SPAIN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 61. SPAIN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 62. SPAIN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 70. CHINA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 71. CHINA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 72. CHINA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. JAPAN ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 74. JAPAN ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 75. JAPAN ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 76. INDIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 77. INDIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 78. INDIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 81. AUSTRALIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 88. LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 89. LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 90. LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 91. LAMEA ANTIEMETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 92. BRAZIL ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 93. BRAZIL ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 94. BRAZIL ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA ANTIEMETICS MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA ANTIEMETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 105.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 106.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 107.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 108.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 109.SANOFI: COMPANY SNAPSHOT
TABLE 110.SANOFI: OPERATING SEGMENTS
TABLE 111.SANOFI: PRODUCT PORTFOLIO
TABLE 112.SANOFI: NET SALES,
TABLE 113.SANOFI: KEY STRATERGIES
TABLE 114.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 115.NOVARTIS AG: OPERATING SEGMENTS
TABLE 116.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 117.NOVARTIS AG: NET SALES,
TABLE 118.NOVARTIS AG: KEY STRATERGIES
TABLE 119.PFIZER INC: COMPANY SNAPSHOT
TABLE 120.PFIZER INC: OPERATING SEGMENTS
TABLE 121.PFIZER INC: PRODUCT PORTFOLIO
TABLE 122.PFIZER INC: NET SALES,
TABLE 123.PFIZER INC: KEY STRATERGIES
TABLE 124.MERCK & CO. INC: COMPANY SNAPSHOT
TABLE 125.MERCK & CO. INC: OPERATING SEGMENTS
TABLE 126.MERCK & CO. INC: PRODUCT PORTFOLIO
TABLE 127.MERCK & CO. INC: NET SALES,
TABLE 128.MERCK & CO. INC: KEY STRATERGIES
TABLE 129.DR. REDDY'S LABORATORIES LTD: COMPANY SNAPSHOT
TABLE 130.DR. REDDY'S LABORATORIES LTD: OPERATING SEGMENTS
TABLE 131.DR. REDDY'S LABORATORIES LTD: PRODUCT PORTFOLIO
TABLE 132.DR. REDDY'S LABORATORIES LTD: NET SALES,
TABLE 133.DR. REDDY'S LABORATORIES LTD: KEY STRATERGIES
TABLE 134.CIPLA: COMPANY SNAPSHOT
TABLE 135.CIPLA: OPERATING SEGMENTS
TABLE 136.CIPLA: PRODUCT PORTFOLIO
TABLE 137.CIPLA: NET SALES,
TABLE 138.CIPLA: KEY STRATERGIES
TABLE 139.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 140.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 141.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 142.JOHNSON & JOHNSON: NET SALES,
TABLE 143.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 144.TORRENT PHARMACEUTICALS LTD: COMPANY SNAPSHOT
TABLE 145.TORRENT PHARMACEUTICALS LTD: OPERATING SEGMENTS
TABLE 146.TORRENT PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 147.TORRENT PHARMACEUTICALS LTD: NET SALES,
TABLE 148.TORRENT PHARMACEUTICALS LTD: KEY STRATERGIES
TABLE 149.ACACIA PHARMA GROUP: COMPANY SNAPSHOT
TABLE 150.ACACIA PHARMA GROUP: OPERATING SEGMENTS
TABLE 151.ACACIA PHARMA GROUP: PRODUCT PORTFOLIO
TABLE 152.ACACIA PHARMA GROUP: NET SALES,
TABLE 153.ACACIA PHARMA GROUP: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.ANTIEMETICS MARKET SEGMENTATION
FIGURE 2.ANTIEMETICS MARKET,2021-2031
FIGURE 3.ANTIEMETICS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.ANTIEMETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.ANTIEMETICS MARKET,BY DRUG TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINES ANTIEMETICS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SEROTONIN RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DOPAMINE RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUROKININ RECEPTOR ANTAGONISTS ANTIEMETICS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTICHOLINERGICS ANTIEMETICS MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHER DRUG TYPES ANTIEMETICS MARKET,2021-2031(%)
FIGURE 19.ANTIEMETICS MARKET,BY APPLICATION,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY ANTIEMETICS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF POST OPERATIVE SURGERY ANTIEMETICS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PREGNANCY AND GATROENTERITIS ANTIEMETICS MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS ANTIEMETICS MARKET,2021-2031(%)
FIGURE 24.ANTIEMETICS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES ANTIEMETICS MARKET,2021-2031(%)
FIGURE 28.ANTIEMETICS MARKET BY REGION,2021
FIGURE 29.U.S. ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 30.CANADA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 31.MEXICO ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 32.GERMANY ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 33.FRANCE ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 34.UK ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 35.ITALY ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 36.SPAIN ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 37.REST OF EUROPE ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 38.CHINA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 39.JAPAN ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 40.INDIA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 41.AUSTRALIA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 42.SOUTH KOREA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 43.REST OF ASIA-PACIFIC ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 44.BRAZIL ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 45.SAUDI ARABIA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 46.SOUTH AFRICA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 47.REST OF LAMEA ANTIEMETICS MARKET,2021-2031($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52.COMPETITIVE DASHBOARD
FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 54.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 55.SANOFI.: NET SALES ,($MILLION)
FIGURE 56.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 57.PFIZER INC.: NET SALES ,($MILLION)
FIGURE 58.MERCK & CO. INC.: NET SALES ,($MILLION)
FIGURE 59.DR. REDDY'S LABORATORIES LTD.: NET SALES ,($MILLION)
FIGURE 60.CIPLA.: NET SALES ,($MILLION)
FIGURE 61.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
FIGURE 62.TORRENT PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
FIGURE 63.ACACIA PHARMA GROUP.: NET SALES ,($MILLION)

Product Code: A00336

The global antiemetics market was valued at $2,251.68 million in 2021, and is projected to reach $4,061.36 million by 2031, registering a CAGR of 6.1% from 2022 to 2031.

Emesis also known as vomiting or throwing up refers to involuntary, forceful expulsion of substances out of the stomach through mouth or sometimes through nose and medications used to stop these involuntary expulsions are known as antiemetics. Seasickness and other motion sicknesses, early pregnancy, intense pain, exposure to chemical toxins, emotional stress (fear), gallbladder disease, food poisoning and indigestion are some of the common causes associated with emesis. In addition, chemotherapy, gastroenteritis, general anesthesia, intestinal obstruction, migraine and others serious ailments may also lead to nausea and vomiting in the patient.

Rise in number of chemotherapies is one of the major driving factor for the growth of the antiemetics market. According to the American Cancer Society (ACS), 609,360 cancer deaths and 1.9 million new cases are anticipated to occur in the United States in 2022. The rate of cancer fatalities for both men and women combined has declined to 32% from its high in 1991 to 2019. The surge in adoption of various cancer therapies by the patient, including chemotherapy and radiation therapy, is mainly responsible for this decline in death rates. The use of chemotherapy and radiation therapy is expected to boost demand for antiemetic medications because these treatments are associated with adverse effects like nausea and vomiting. Thus, it is anticipated that a high prevalence of cancer cases and extensive use of chemotherapy as the treatment option will fuel the global antiemetics market during the forecast period.

Furthermore, rise in funding by governments of various countries and private organizations to initiate manufacturing units are expected to boost the market growth. Also, the government organizations of the respective countries are proving funds to carry out the research and development for the new molecules, which boost the growth of the market in that region. In addition, acquisition and partnerships by the key market players are the boosting factors for the market. These key strategies are mainly adopted by the key market players to expand their business and their product portfolio, which leads to increase in sales of the company, along with the growth of the market.

Additionally, the occurrence of gastroenteritis, often known as stomach flu, contributes to market growth. Gastroenteritis is an inflammation of the stomach and intestines that is typically brought on by viruses, bacteria, or parasites infected food or water. It produces nausea, fever, cramps, nausea, and headaches in addition to stomach discomfort and cramping. Additionally, Norovirus is a prominent source of gastroenteritis and foodborne disease outbreaks in the United States, which causes nausea and vomiting in the patients. This prevalence of Norovirus infection, demands for the antiemetics treatment medications, which is driving up sales of antiemetics in this region and boosting market growth overall.

However, less awareness about antiemetic drugs among the population hinders growth of the market. In some cases, the strength, dose and drug class of the prescribed antiemetics may lead to the severe condition in the patients, which demands for the proper knowledge regarding the medicine and its pharmacology, which can act as a restraint to the antiemetics market. On the contrary, rise in research and development activities by key market players and increase in healthcare expenditure has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the antiemetics market. Also, the presence of raw material in the developing regions such as Asia and LAMEA, provides lucrative opportunities for the market players to invest in this region.

The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global Antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy's Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

Antihistamines
Serotonin Receptor Antagonists
Dopamine Receptor Antagonists
Neurokinin Receptor Antagonists
Anticholinergics
Other Drug Types

By Application

Chemotherapy
Post Operative Surgery
Pregnancy and Gatroenteritis
Other Applications

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- GlaxoSmithKline Plc
- Sanofi
- Novartis AG
- Pfizer Inc
- Merck & Co. Inc
- Dr. Reddy's Laboratories Ltd
- Cipla
- Johnson & Johnson
- Torrent Pharmaceuticals Ltd
- Acacia Pharma Group

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Antihistamines
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Serotonin Receptor Antagonists
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Dopamine Receptor Antagonists
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Neurokinin Receptor Antagonists
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
4.6 Anticholinergics
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
4.7 Other Drug Types
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country

CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Chemotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Post Operative Surgery
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Pregnancy and Gatroenteritis
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Other Applications
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country

CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Retail Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Hospital Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: ANTIEMETICS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Type
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Drug Type
  - 7.2.5.1.2 Market size and forecast, by Application
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Drug Type
  - 7.2.5.2.2 Market size and forecast, by Application
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Drug Type
  - 7.2.5.3.2 Market size and forecast, by Application
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Type
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Drug Type
  - 7.3.5.1.2 Market size and forecast, by Application
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Drug Type
  - 7.3.5.2.2 Market size and forecast, by Application
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Drug Type
  - 7.3.5.3.2 Market size and forecast, by Application
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Drug Type
  - 7.3.5.4.2 Market size and forecast, by Application
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Drug Type
  - 7.3.5.5.2 Market size and forecast, by Application
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Drug Type
  - 7.3.5.6.2 Market size and forecast, by Application
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 China
  - 7.4.5.1.1 Market size and forecast, by Drug Type
  - 7.4.5.1.2 Market size and forecast, by Application
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 Japan
  - 7.4.5.2.1 Market size and forecast, by Drug Type
  - 7.4.5.2.2 Market size and forecast, by Application
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Drug Type
  - 7.4.5.3.2 Market size and forecast, by Application
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Drug Type
  - 7.4.5.4.2 Market size and forecast, by Application
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Drug Type
  - 7.4.5.5.2 Market size and forecast, by Application
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Drug Type
  - 7.4.5.6.2 Market size and forecast, by Application
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Type
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Drug Type
  - 7.5.5.1.2 Market size and forecast, by Application
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Drug Type
  - 7.5.5.2.2 Market size and forecast, by Application
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Drug Type
  - 7.5.5.3.2 Market size and forecast, by Application
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Drug Type
  - 7.5.5.4.2 Market size and forecast, by Application
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 GlaxoSmithKline Plc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Sanofi
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Novartis AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Pfizer Inc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Merck & Co. Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Dr. Reddy's Laboratories Ltd
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Cipla
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Johnson & Johnson
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Torrent Pharmaceuticals Ltd
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Acacia Pharma Group
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

制吐剤市場：薬剤タイプ別、用途別、流通チャネル別：世界の機会分析・産業予測、2021-2031年

Antiemetics Market By Drug Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章制吐剤市場：薬剤タイプ別

第5章制吐剤市場：用途別

第6章制吐剤市場：流通チャネル別

第7章制吐剤市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE

CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION

CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: ANTIEMETICS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

制吐剤市場：薬剤タイプ別、用途別、流通チャネル別：世界の機会分析・産業予測、2021-2031年

Antiemetics Market By Drug Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章制吐剤市場：薬剤タイプ別

第5章 制吐剤市場：用途別

第6章 制吐剤市場：流通チャネル別

第7章 制吐剤市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE

CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION

CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: ANTIEMETICS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第5章制吐剤市場：用途別

第6章制吐剤市場：流通チャネル別

第7章制吐剤市場：地域別

第8章企業情勢

第9章企業プロファイル